Clinical research plays a crucial role in the field of medicine and in improving patient care. It involves conducting trials to explore new treatments, medications, and interventions. These research efforts contribute to enhancing medical knowledge, developing innovative therapies, and ultimately saving lives in cancer care.
At Mahatma Gandhi Cancer Hospital and Research Institute, we thrive on improving patient treatment outcomes by actively participating in various trials. Since our establishment in 2006, we have recognized the importance of clinical trials and initiated research activities in 2007.
Various studies have been carried out at our institute since 2007. Our clinical research department has completed more than 50 sponsor-driven clinical trials (both national and international studies). Currently, 12 Ongoing Trials, including One Principal Investigator (PI) Driven Trial are underway. The studies are across medical, surgical, and radiation oncology departments.
Some of our primary sponsors are AstraZeneca Pharma India Limited, Labcorp Drug Development, CBCC Global Research LLP, Lambda Therapeutic Research Ltd., etc. Phase II, III, IV, and BA, BE clinical trials have been carried out successfully.
Our constant endeavor towards research is demonstrated by our active participation in various clinical studies, which is helping us to stay at the forefront of medical advancements. Our commitment and involvement help improve patient outcomes.
The continuous efforts and dedication of the clinical research department are paving the way for groundbreaking discoveries and bringing new hope to patients. Staying focused on current research advancements helps us deliver the highest quality care to patients with access to the latest advancements in medical science.
A few major studies were carried out on:
- Breast Cancer
- Advanced Ovarian Cancer
- Cervical Cancer
- Renal Cell Carcinoma
- Head & Neck Carcinomas
- Non-Hodgkins Lymphoma
- Metastatic Colorectal Cancer
- Recurrent or Advanced Non-Squamous Non-Small Cell Lung Cancer(NSCLC)
- Relapsed Multiple Myeloma
- Castration-Resistant Prostate Cancer
- Myelodysplastic Syndrome(MDS)
- Hepatocellular Carcinoma (HCC)
- Immune Thrombocytopenic Purpura (ITP)
In 2009, more than 100 subjects were screened and randomized in a gastric and gastro-oesophageal cancer study. MGCH&RI is the highest recruiter for the study.
Later on, in 2015, a study on Doxorubicin Hydrochloride (Pegylated Liposomal) trial in advanced ovarian cancer and/or metastatic breast cancer patients was carried out. A total of 24 subjects were screened for the study, and 18 patients were randomized.
Participating in the latest clinical studies is a continuous process, and we at Mahatma Gandhi Cancer Hospital & Research Institute are always motivated to achieve the best results from time to time. In this process, in the year 2022, a HER2+ MBC study was conducted in our center. Thirty-three patients were screened and 27 patients were randomized, and we are the 3rd highest recruiter in this study.
We appreciate ourselves for working towards every ultima of the process and consistently participating in various clinical trials. This enthusiastic approach helps in the betterment of cancer care.
All the research proposals submitted to Mahatma Gandhi Cancer Hospital & Research Institute are properly reviewed by the internal committee before being forwarded to the Institutional Ethics Committee (IEC) for ethical clearance.
Our IEC, ‘Mahatma Gandhi Cancer Hospital & Research Institute Institutional Review Board’ was approved by DGCI and is valid till February 2025.
We have the Department of Health Research Registration Certificate (DHR), approved by the National Ethics Committee Registry for Biomedical and Health Research, for DNB students, and it is valid till May-2028.
At Mahatma Gandhi Cancer Hospital and Research Institute, the research staff are the key people who make it all work. In this team, we have 4 medical oncologists, 4 surgical oncologists, and 5 radiation oncologists serving as research consultants. We have 9 members working on our clinical research team. In that, a four-member qualified research staff serving as CRCs, along with an experienced clinical research manager, blinded and unblinded study nurses, a phlebotomist, and a dedicated EC coordinator, make our clinical research wing stronger.
Apart from clinical trials, Mahatma Gandhi Cancer Hospital & Research Institute is also involved in basic and translation research by collaborating with various educational and medical institutions like Andhra University, GITAM (Deemed to be University), Gayathri Vidhya Parishad Medical College, Gayathri Vidhya Parishad, etc. Internship Students from different Universities and Colleges like Andhra University, GITAM (Deemed to be a University), Centurion University, Gayathri Vidhya Parishad, etc. are posted at Mahatma Gandhi Cancer Hospital & Research Institute across various departments. The interns are actively engaged in various prospective and retrospective research studies.
Mahatma Gandhi Cancer Hospital & Research Institute is tied up with the Ramesh Nimmagadda Cancer Foundation and is actively contributing clinical data to OncoCollect software. Our recent Memorandum of Understanding (MoU) with Genome Foundation, Hyderabad, paved the way to expand our research activities. We are participating in a Triple Negative Breast Cancer study to understand the treatment outcomes. Mahatma Gandhi Cancer Hospital & Research Institute is keen on bridging the gap in translational research, and we are in the process of applying for a DSIR/SIRO registration.
- Stage IIIB/IV Non-Squamous (ns) Non-Small Cell Lung Cancer
- Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Unresectable Transitional Cell Urothelial Carcinoma
- Locally advanced or metastatic breast cancer after failure to prior chemotherapy
- Advanced prostate cancer
- Advanced Breast cancer
- Ovarian cancer or breast cancer or pancreatic cancer or prostate cancer who are eligible to receive Olaparib under fasting conditions
- Locally advanced or Metastatic Non-Small Cell Lung Cancer
- HER2-Positive Metastatic Breast Cancer